Smital Shah - 09 Mar 2026 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Reporting relationship: Chief Fin. and Bus. Officer
Issuer ticker: LYEL
Reported as of: 09 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Mar 2026, 19:26:24 UTC
Prior SEC filing: 17 Jun 2024
Source filing: View source filing
Reporting owner signature: /s/ Mark Meltz, Attorney-in-Fact

Key filing fact

Smital Shah filed Form 4 for Lyell Immunopharma, Inc. (LYEL) on 16 Mar 2026.

Key facts

This page summarizes Smital Shah's Form 4 filing for Lyell Immunopharma, Inc. (LYEL).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 16 Mar 2026, 19:26.

Change

Previous filing in this sequence was filed on 17 Jun 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001808821 Primary reporting owner

Shah Smital

Relationship: Chief Fin. and Bus. Officer
Address: C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SUITE 101, SOUTH SAN FRANCISCO
Signature: /s/ Mark Meltz, Attorney-in-Fact
Signature date: 16 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LYEL transaction Derivative

Option (right to buy)

Award

Transaction value
Shares: +140,000
Change %
Price: $0.000000^*
Shares after: 140,000
Date: 09 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 140,000
Exercise price: $25.50
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25% of the option shares will vest on March 9, 2027, with the remaining option shares to vest in equal monthly installments over the following 36 months, subject to the reporting person providing service through the applicable vesting date.